# Space exploration and lifestyle medicine: a narrative review of its implications for astronaut health and remote Earth-based environments

**Authors:** Raphaëlle Giguère, Alexandre Marois, Daniel Fortin-Guichard, Jonathan Charest, Julie Rocheleau, Keith Thompson, Michael Stolberg, Philippe St-Martin, Audrey Bergouignan, Victor Niaussat, Jean-Sébastien Paquette, Marie-Pierre Gagnon, Maxime Sasseville, Caroline Rhéaume

PMC · DOI: 10.3389/fphys.2025.1729596 · 2026-01-13

## TL;DR

This paper explores how lifestyle medicine can improve astronaut health during long space missions and also benefit people in remote areas on Earth.

## Contribution

The paper introduces a novel framework integrating lifestyle medicine with space medicine for health prevention in extreme environments.

## Key findings

- Lifestyle medicine pillars face unique challenges in space, such as limited food variety and microgravity.
- Technological innovations like wearables and virtual reality can support integrated lifestyle medicine in space and remote Earth settings.
- Applying lifestyle medicine could reduce healthcare disparities and improve preventive care in underserved areas.

## Abstract

Space exploration, especially long-duration missions such as those to Mars, presents unique and significant challenges to astronaut health. Space medicine, which focuses on maintaining health in extreme environments without access to definitive medical care, emphasizes preventive measures. Lifestyle medicine (LM), grounded in six pillars such as healthy nutrition, regular physical activity, restorative sleep, stress management, positive social connections, and avoidance of risky substances, has proven effective for disease prevention on Earth. However, its application to spaceflight and remote Earth environments remains underexplored. This raises the question of how LM framework can sustain astronaut health and inform preventive and primary care strategies for remote Earth populations.

This narrative review examines how LM can support astronaut health during long-duration missions and draws parallels with healthcare needs in remote Earth populations. It establishes principles for integrating lifestyle and space medicine and provides recommendations for their application in both contexts.

Each LM pillar is uniquely challenged in space. Nutritional constraints arise from limited food variety and storage capacity; microgravity and workload restrictions limit physical activity; circadian disruption and environmental noise affect sleep; isolation, confinement, and mission stress compromise stress regulation and social connections; restricted crew size and communication delays limit social connection; and strict medication policies highlight the dual role of substance use as both risks and necessity. While individual countermeasures have been tested in space, no integrated framework addressing all pillars simultaneously has yet been implemented. Technological innovations, such as wearable devices for continuous monitoring, telehealth modules for remote support, and virtual reality platforms for mental health and social engagement, appear as promising enablers of such an integrated approach for both astronauts and populations in medically underserved areas on Earth.

LM provides a preventive framework that complements traditional countermeasure and may enhance resilience and autonomy during space missions. Future research should prioritize integrated, longitudinal studies in analog environments to quantify the synergistic effects of integrated LM interventions versus single pillar countermeasures. Its translation to remote and underserved populations on Earth could help reduce healthcare disparities and support scalable, autonomy-centered models of care, underscoring the bidirectional value of combining lifestyle and space medicine.

## Full-text entities

- **Genes:** CRH (corticotropin releasing hormone) [NCBI Gene 1392] {aka CRF, CRH1}, HCRT (hypocretin neuropeptide precursor) [NCBI Gene 3060] {aka NRCLP1, OX, PPOX}
- **Diseases:** sleepiness (MESH:D000077260), noncommunicable diseases (MESH:D000073296), dementia (MESH:D003704), mental health disorders (OMIM:603663), muscle loss (MESH:D009135), hyperlipidemia (MESH:D006949), sleep deprivation (MESH:D012892), burnout (MESH:D002055), circadian disruption (MESH:D019958), cancers (MESH:D009369), difficulty concentrating (MESH:C567712), chronic (MESH:D002908), micronutrient loss (MESH:D016388), PTSD (MESH:D013313), insomnia (MESH:D007319), atrophy of certain brain regions (MESH:C566985), fatigue (MESH:D005221), cardiometabolic disease (MESH:D024821), anorexia (MESH:D000855), liver ectopic adipocytes (MESH:D017093), lower back pain (MESH:D017116), deficits in manual dexterity (MESH:D009461), burn (MESH:D002056), hypertension (MESH:D006973), -related (MESH:D019973), appetite suppression (MESH:D001068), arrhythmia (MESH:D001145), muscle hypertrophy (MESH:C536106), endothelial dysfunction (MESH:D014652), inflammation (MESH:D007249), memory problems (MESH:D008569), substance misuse (MESH:D009293), anxiety (MESH:D001007), hippocampal damage (MESH:D000092223), decline (MESH:D060825), insulin resistance (MESH:D007333), stroke (MESH:D020521), acidosis (MESH:D000138), excessive sleepiness (MESH:D006970), circadian misalignment (MESH:D017760), death (MESH:D003643), depression (MESH:D003866), obesity (MESH:D009765), chronic fatigue (MESH:D015673), hyperinsulinemia (MESH:D006946), ACLM (MESH:D006478), heart disease (MESH:D006331), cognitive disorders (MESH:D003072), bone decalcification (MESH:D003649), sleep deficiency (MESH:D012893), Muscle atrophy (MESH:D009133), Mental Disorders (MESH:D001523), substance use disorders (MESH:D019966), muscle (MESH:D019042), glucose intolerance (MESH:D018149), cardiovascular deconditioning (MESH:D002318), alcohol misuse (MESH:D000437), neurodegeneration (MESH:D019636), Stress (MESH:D000079225), atherosclerosis (MESH:D050197)
- **Chemicals:** Caffeine (MESH:D002110), sodium (MESH:D012964), amino acids (MESH:D000596), zaleplon (MESH:C085665), vitamin D (MESH:D014807), CO2 (MESH:D002245), flurazepam (MESH:D005479), carbohydrate (MESH:D002241), quetiapine fumarate (MESH:D000069348), aldosterone (MESH:D000450), Modafinil (MESH:D000077408), melatonin (MESH:D008550), vitamin K (MESH:D014812), beta-hydroxy-beta-methylbutyrate (MESH:C004961), sugars (MESH:D000073893), LM (-), amphetamine (MESH:D000661), calcium (MESH:D002118), zolpidem (MESH:D000077334), cortisol (MESH:D006854), Dextroamphetamine (MESH:D003913), alcohol (MESH:D000438), lipid (MESH:D008055), norepinephrine (MESH:D009638), eszopiclone (MESH:D000069582), temazepam (MESH:D013693), potassium (MESH:D011188), benzodiazepine (MESH:D001569)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12834740